Compositions and method are disclosed for treating in a subject diseases associated with aberrant integrin avß3 activity. The methods involve administering to the subject an effective amount of a composition comprising a pyruvate kinase isoform M2 (PKM2) antagonist that inhibits the binding of PKM2 to integrin avß3.